-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression
Original Research
(2603) Views (610) Full article downloads
Authors: Hisashi Higuchi, Hitoshi Takahashi, Mitsuhiro Kamata, Keizo Yoshida
Published Date July 2009
Volume 2009:5 Pages 393 - 398
DOI: http://dx.doi.org/10.2147/NDT.S4369
Hisashi Higuchi1, Hitoshi Takahashi2, Mitsuhiro Kamata3, Keizo Yoshida4
1Department of Psychiatry, St. Marianna University, School of Medicine, Kanagawa, Japan; 2Department of Psychiatry, Tokyo Women’s Medical University, School of Medicine, Tokyo, Japan; 3Department of Psychiatry, Yuri-Kumiai General Hospital, Yuri-Honjo, Akita, Japan; 4Department of Psychiatry, Nagoya University School of Medicine, Aichi, Japan
Abstract: The present study was conducted to find out the predictors of side effects such as nausea and excessive sweating induced by milnacipran, a serotonin/norepinephrine reuptake inhibitor. Both clinical characteristics prior to the treatment and gene polymorphisms such as serotonin transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number of tandem repeats in the second intron of the 5-HTT gene (5-HTTVNTR), 5-HT2A receptor gene (5-HT2A G-1438A), a TPH gene polymorphism in intron 7 (TPH A218C), norepinephrine transporter (NET) gene polymorphism in the promoter region (NET T-182C) and in the exon 9 (NET G1287A), a variable number of tandem repeats in the promoter region of monoamine oxidase A, were items to be assessed in this study. Ninety-six patients with major depressive disorder were treated with milnacipran. Side effects were assessed at 1, 2, 4, and 6 weeks of treatment with Udvalg for Kliniske Undersogelser side effects scale. The results showed that no gene polymorphisms included in this study affected the susceptibility of nausea and excessive sweating induced by milnacipran. Patients with older age are more likely to develop excessive sweating than others. The major limitation of this study is a small sample size. Further studies with larger populations and more kinds of gene polymorphisms should be needed to see if specific gene polymorphisms determine the susceptibility of side effects induced by milnacipran.
Keywords: milnacipran, nausea, excessive sweating, gene polymorphisms
Readers of this article also read:
Brain-derived neurotrophic factor: role in depression and suicide
The pathophysiology of bronchiectasis
Health literacy and health seeking behavior among older men in a middle-income nation
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Perception of risk and benefit in patient-centered communication and care
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




